|
Exhibit
10.1
NOTE PURCHASE
AGREEMENT
VALENS U.S. SPV I,
LLC
and
BIOVEST INTERNATIONAL,
INC.
Dated: October 30,
2007
TABLE OF
CONTENTS
|
|
|
|
|
|
|
| |
|
|
|
|
|
Page |
|
1.
|
|
Agreement to Sell and Purchase |
|
1 |
|
|
|
|
2.
|
|
Fees |
|
1 |
|
|
|
|
3.
|
|
Closing, Delivery and Payment |
|
2 |
|
|
3.1
|
|
Closing |
|
2 |
|
|
3.2
|
|
Delivery |
|
2 |
|
|
|
|
4.
|
|
Representations and Warranties of the Company |
|
2 |
|
|
4.1
|
|
Organization, Good Standing and Qualification |
|
2 |
|
|
4.2
|
|
Subsidiaries |
|
3 |
|
|
4.3
|
|
Capitalization; Voting Rights |
|
3 |
|
|
4.4
|
|
Authorization; Binding Obligations |
|
4 |
|
|
4.5
|
|
Liabilities |
|
4 |
|
|
4.6
|
|
Agreements; Action |
|
4 |
|
|
4.7
|
|
Obligations to Related Parties |
|
6 |
|
|
4.8
|
|
Changes |
|
6 |
|
|
4.9
|
|
Title to
Properties and Assets; Liens, Etc |
|
8 |
|
|
4.10
|
|
Intellectual Property |
|
8 |
|
|
4.11
|
|
Compliance with Other Instruments |
|
9 |
|
|
4.12
|
|
Litigation |
|
9 |
|
|
4.13
|
|
Tax
Returns and Payments |
|
9 |
|
|
4.14
|
|
Employees |
|
10 |
|
|
4.15
|
|
Registration Rights and Voting Rights |
|
10 |
|
|
4.16
|
|
Compliance with Laws; Permits |
|
10 |
|
|
4.17
|
|
Environmental and Safety Laws |
|
11 |
|
|
4.18
|
|
Valid
Offering |
|
11 |
|
|
4.19
|
|
Full
Disclosure |
|
11 |
|
|
4.20
|
|
Insurance |
|
12 |
|
|
4.21
|
|
SEC
Reports |
|
12 |
|
|
4.22
|
|
Listing |
|
12 |
|
|
4.23
|
|
No
Integrated Offering |
|
12 |
|
|
4.24
|
|
Stop
Transfer |
|
12 |
|
|
4.25
|
|
Patriot
Act |
|
13 |
|
|
4.26
|
|
ERISA |
|
13 |
|
|
|
|
5.
|
|
Representations and Warranties of the Purchaser |
|
14 |
|
|
5.1
|
|
Incorporation; No Shorting |
|
14 |
|
|
5.2
|
|
Requisite
Power and Authority |
|
14 |
|
|
5.3
|
|
Investment Representations |
|
14 |
|
|
5.4
|
|
The
Purchaser Bears Economic Risk |
|
14 |
|
|
5.5
|
|
Acquisition for Own Account |
|
15 |
i
|
|
|
|
|
|
|
|
|
5.6
|
|
The
Purchaser Can Protect Its Interest |
|
15 |
|
|
5.7
|
|
Accredited Investor |
|
15 |
|
|
|
|
6.
|
|
Covenants of the Company |
|
15 |
|
|
6.1
|
|
Listing |
|
15 |
|
|
6.2
|
|
Market
Regulations |
|
15 |
|
|
6.3
|
|
Reporting
Requirements |
|
15 |
|
|
6.4
|
|
Use of
Funds |
|
17 |
|
|
6.5
|
|
Access to
Facilities |
|
17 |
|
|
6.6
|
|
Taxes |
|
17 |
|
|
6.7
|
|
Insurance |
|
17 |
|
|
6.8
|
|
Intellectual Property |
|
18 |
|
|
6.9
|
|
Properties |
|
19 |
|
|
6.10
|
|
Confidentiality |
|
19 |
|
|
6.11
|
|
Required
Approvals |
|
19 |
|
|
6.12
|
|
Opinion |
|
21 |
|
|
6.13
|
|
Margin
Stock |
|
21 |
|
|
|
|
7.
|
|
Covenants of the Purchaser |
|
21 |
|
|
7.1
|
|
Confidentiality |
|
21 |
|
|
7.2
|
|
Non-Public Information |
|
22 |
|
|
7.3
|
|
Limitation on Acquisition of Common Stock of the
Company |
|
22 |
|
|
|
|
8.
|
|
Covenants of the Company and the Purchaser Regarding
Indemnification |
|
22 |
|
|
8.1
|
|
Company
Indemnification |
|
22 |
|
|
8.2
|
|
Purchaser’s Indemnification |
|
22 |
|
|
|
|
9.
|
|
Intentionally Omitted |
|
23 |
|
|
9.1
|
|
Intentionally Omitted |
|
23 |
|
|
|
|
10.
|
|
Intentionally Omitted |
|
23 |
|
|
|
|
11.
|
|
Miscellaneous |
|
23 |
|
|
11.1
|
|
Governing
Law, Jurisdiction and Waiver of Jury Trial |
|
23 |
|
|
11.2
|
|
Severability |
|
24 |
|
|
11.3
|
|
Survival |
|
24 |
|
|
11.4
|
|
Successors |
|
24 |
|
|
11.5
|
|
Entire
Agreement; Maximum Interest |
|
25 |
|
|
11.6
|
|
Amendment
and Waiver |
|
25 |
|
|
11.7
|
|
Delays or
Omissions |
|
25 |
|
|
11.8
|
|
Notices |
|
25 |
|
|
11.9
|
|
Attorneys’ Fees |
|
26 |
|
|
11.10
|
|
Titles
and Subtitles |
|
26 |
|
|
11.11
|
|
Facsimile
Signatures; Counterparts |
|
27 |
|
|
11.12
|
|
Broker’s Fees |
|
27 |
|
|
11.13
|
|
Construction |
|
27 |
ii
LIST OF
EXHIBITS
|
|
|
|
Form of Secured Promissory
Note
|
|
Exhibit A |
|
Form of Escrow Agreement
|
|
Exhibit B |
LIST OF
SCHEDULES
|
|
|
|
Subsidiary
|
|
Schedule 4.2 |
|
Capital Stock of Company and
Subsidiary
|
|
Schedule 4.3 |
|
Agreements
|
|
Schedule 4.6 |
|
Obligations to Related
Parties
|
|
Schedule 4.7 |
|
Title; liens
|
|
Schedule 4.9 |
|
Litigation
|
|
Schedule 4.12 |
|
Tax Returns and Payments
|
|
Schedule 4.13 |
|
Employees
|
|
Schedule 4.14 |
|
Registration Rights; Voting
Rights
|
|
Schedule 4.15 |
|
Environmental and Safety Laws
|
|
Schedule 4.17 |
|
SEC Reports
|
|
Schedule 4.21 |
|
Indebtedness
|
|
Schedule 6.11(I)(e) |
|
Broker’s Fees
|
|
Schedule 11.12 |
iii
NOTE PURCHASE
AGREEMENT
THIS NOTE PURCHASE AGREEMENT
(this “ Agreement ”) is made and entered into as
of October 30, 2007, by and between BIOVEST INTERNATIONAL,
INC., a Delaware corporation (the “ Company ”),
and VALENS U.S. SPV I, LLC, a Delaware corporation (the “
Purchaser ”).
RECITALS
WHEREAS, the Company has
authorized the sale to the Purchaser of a Secured Promissory Note
in the aggregate principal amount of Two Hundred Forty-Five
Thousand and 00/100 Dollars ($245,000) in the form of Exhibit A
hereto (as amended, modified and/or supplemented from time to time,
the “ Note ”);
WHEREAS, the Purchaser
desires to purchase the Note on the terms and conditions set forth
herein; and
WHEREAS, the Company desires
to issue and sell the Note to the Purchaser on the terms and
conditions set forth herein.
AGREEMENT
NOW, THEREFORE, in
consideration of the foregoing recitals and the mutual promises,
representations, warranties and covenants hereinafter set forth and
for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:
1. Agreement to Sell and
Purchase . Pursuant to the terms and conditions set forth in
this Agreement, on the Closing Date (as defined in Section 3),
the Company shall sell to the Purchaser, and the Purchaser shall
purchase from the Company, the Note. The sale of the Note on the
Closing Date shall be known as the “ Offering .”
The Note will mature on the Maturity Date (as defined in the Note).
The Note is sometimes referred to herein as the “
Securities .”
2. Fees . On the
Closing Date, the Company shall pay (i) to Valens Capital
Management, LLC, the investment manager of the Purchaser (“
VCM ”), a non-refundable payment in an amount equal to
$3675.00, plus reasonable expenses (including legal fees and
expenses) incurred in connection with the entering into of this
Agreement and the Related Agreements and expenses incurred in
connection with each of VCM and/or Purchaser’s due diligence
review of the Company and all other related matters; (ii) to
the Purchaser, a non-refundable payment in an amount equal to
$2,450.00; and (iii) to the Purchaser, an advance prepayment
discount deposit equal to $2,450.00. Each of the foregoing payments
in clauses (i) and (ii) above shall be deemed fully
earned on the Closing Date and shall not be subject to rebate or
proration for any reason. The payments set forth in clause
(i) (net of any deposits previously paid by the Company) and
clause (ii) and (iii) above, shall be paid at closing out
of funds held pursuant to the Escrow Agreement (as defined below)
and a disbursement letter (the “ Disbursement Letter
”).
3. Closing, Delivery and
Payment .
3.1 Closing . Subject
to the terms and conditions herein, the closing of the transactions
contemplated hereby (the “ Closing ”), shall
take place on the date hereof, at such time or place as the Company
and the Purchaser may mutually agree (such date is hereinafter
referred to as the “Closing Date”).
3.2 Delivery .
Pursuant to the Escrow Agreement, at the Closing on the Closing
Date, the Company will deliver to the Purchaser, among other
things, the Note and the Purchaser will deliver to the Company,
among other things, the amounts set forth in the Disbursement
Letter by certified funds or wire transfer and disbursed in
accordance with the terms set forth in the Note. The Company hereby
acknowledges and agrees that Purchaser’s obligation to
purchase the Note from the Company on the Closing Date shall be
contingent upon the satisfaction (or waiver by the Purchaser in its
sole discretion) of the items and matters set forth in the closing
checklist provided by the Purchaser to the Company on or prior to
the Closing Date.
4. Representations and
Warranties of the Company . The Company hereby represents and
warrants to the Purchaser as follows
4.1 Organization, Good
Standing and Qualification . Each of the Company and each of
its Subsidiaries is a corporation, partnership or limited liability
company, as the case may be, duly organized, validly existing and
in good standing under the laws of its jurisdiction of
organization. Each of the Company and each of its Subsidiaries has
the corporate, limited liability company or partnership, as the
case may be, power and authority to own and operate its properties
and assets and, insofar as it is or shall be a party thereto, to
(1) execute and deliver (i) this Agreement, (ii) the
Note, (iii) the Master Security Agreement dated as of the date
hereof between the Company and its Subsidiaries and LV
Administrative Services, Inc., as agent (the “Agent”)
for the Purchaser (as amended, modified and/or supplemented from
time to time, the “ Master Security Agreement ”
and together with each other security agreement, mortgage, pledge
and other similar agreements which are executed by the Company or
any of its Subsidiaries in favor of the Agent and/or the Purchaser,
collectively, the “ Security Documents ”),
(iv) the Royalty Agreement dated as of the date hereof between
the Company and the Purchaser (as amended, modified and/or
supplemented from time to time, the “ Royalty
Agreement ”), (v) the Funds Escrow Agreement dated
as of the date hereof among the Company, the Purchaser and the
escrow agent referred to therein, substantially in the form of
Exhibit B hereto (as amended, modified and/or supplemented from
time to time, the “ Escrow Agreement ”), and
(vi) all other documents, instruments and agreements entered
into in connection with the transactions contemplated hereby and
thereby (the preceding clauses (ii) through (vi),
collectively, the “ Related Agreements ”);
(2) issue and sell the Note; and (3) carry out the
provisions of this Agreement and the Related Agreements and to
carry on its business as presently conducted. Each of the Company
and each of its Subsidiaries is duly qualified and is authorized to
do business and is in good standing as a foreign corporation,
partnership or limited liability company, as the case may be, in
all jurisdictions in which the nature or location of its activities
and of its properties (both owned and leased) makes such
qualification necessary, except for those jurisdictions in which
failure to do so has not, or could not reasonably be expected to
have, individually or in the aggregate, a material adverse effect
on the business, assets, liabilities, condition (financial or
otherwise), properties, operations or prospects of the Company and
its Subsidiaries, taken individually and as a whole (a “
Material Adverse Effect ”).
2
4.2 Subsidiaries .
Each direct and indirect Subsidiary of the Company, the direct
owner of such Subsidiary and its percentage ownership thereof, is
set forth on Schedule 4.2. For the purpose of this Agreement,
(x) a “ Subsidiary ” of any person or
entity means (i) a corporation or other entity whose shares of
stock or other ownership interests having ordinary voting power
(other than stock or other ownership interests having such power
only by reason of the happening of a contingency) to elect a
majority of the directors of such corporation, or other persons or
entities performing similar functions for such person or entity,
are owned, directly or indirectly, by such person or entity or
(ii) a corporation or other entity in which such person or
entity owns, directly or indirectly, more than 50% of the equity
interests at such time and (y) a “ Credit Party
” means, the Company and each direct or indirect Subsidiary
of the Company to the extent party to any Security Document
required by the Purchaser to grant to the Purchaser a first
priority perfected security interest in substantially all of such
Subsidiary’s assets to secure the Obligations (as defined in
each Security Document).
4.3 Capitalization; Voting
Rights .
(a) The authorized capital
stock of the Company, as of the date hereof consists of 350,000,000
shares, of which 300,000,000 are shares of Common Stock, par value
$0.01 per share, 80,390,663 shares of which are issued and
outstanding, and 50,000,000 are shares of preferred stock, par
value $0.01 per share of which no shares of preferred stock are
issued and outstanding. The authorized, issued and outstanding
capital stock of each Subsidiary of the Company is set forth on
Schedule 4.3.
(b) Except as disclosed on
Schedule 4.3, other than: (i) the shares reserved for issuance
under the Company’s stock option plans; and (ii) shares
which may be granted pursuant to this Agreement and the Related
Agreements, there are no outstanding options, warrants, rights
(including conversion or preemptive rights and rights of first
refusal), proxy or stockholder agreements, or arrangements or
agreements of any kind for the purchase or acquisition from the
Company of any of its securities. Except as disclosed on Schedule
4.3, neither the offer, issuance or sale of the Note, nor the
consummation of any transaction contemplated hereby will result in
a change in the price or number of any securities of the Company
outstanding, under anti-dilution or other similar provisions
contained in or affecting any such securities.
(c) All issued and
outstanding shares of the Company’s Common Stock:
(i) have been duly authorized and validly issued and are fully
paid and nonassessable; and (ii) were issued in compliance
with all applicable state and federal laws concerning the issuance
of securities.
(d) The rights, preferences,
privileges and restrictions of the shares of the Common Stock are
as stated in the Company’s Certificate of Incorporation (the
“ Charter ”). When issued in compliance with the
provisions of this Agreement and the Company’s Charter, the
Securities will be validly issued, fully paid and nonassessable,
and will be free of any liens or encumbrances; provided ,
however , that the Securities may be subject to restrictions
on transfer under state and/or federal securities laws as set forth
herein or as otherwise required by such laws at the time a transfer
is proposed.
3
4.4 Authorization; Binding
Obligations . All corporate, partnership or limited liability
company, as the case may be, action on the part of the Company and
each of its Subsidiaries (including their respective officers and
directors) necessary for the authorization of this Agreement and
the Related Agreements, the performance of all obligations of the
Company and its Subsidiaries hereunder and under the other Related
Agreements at the Closing and, the authorization, sale, issuance
and delivery of the Note has been taken or will be taken prior to
the Closing. This Agreement and the Related Agreements, when
executed and delivered and to the extent it is a party thereto,
will be valid and binding obligations of each of the Company and
each of its Subsidiaries, enforceable against each such person or
entity in accordance with their terms, except:
(a) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium or other laws of
general application affecting enforcement of creditors’
rights; and
(b) general principles of
equity that restrict the availability of equitable or legal
remedies.
The sale of the Note is not and will not
be subject to any preemptive rights or rights of first refusal that
have not been properly waived or complied with.
4.5 Liabilities .
Neither the Company nor any of its Subsidiaries has any
liabilities, except current liabilities incurred in the ordinary
course of business and liabilities disclosed in any of the
Company’s filings under the Securities Exchange Act of 1934
(“ Exchange Act ”) made prior to the date of
this Agreement (collectively, the “ Exchange Act
Filings ”), copies of which have been provided to the
Purchaser.
4.6 Agreements; Action
. Except (i) as set forth on Schedule 4.6, or (ii) as
disclosed in any Exchange Act Filings:
(a) there are no agreements,
understandings, instruments, contracts, proposed transactions,
judgments, orders, writs or decrees to which the Company or any of
its Subsidiaries is a party or by which it is bound which may
involve: (i) obligations (contingent or otherwise) of, or
payments to, the Company or any of its Subsidiaries in excess of
$50,000 (other than obligations of, or payments to, the Company or
any of its Subsidiaries arising from purchase or sale agreements
entered into in the ordinary course of business); or (ii) the
transfer or license of any patent, copyright, trade secret or other
proprietary right to or from the Company or any of its Subsidiaries
(other than licenses arising from the purchase of “off the
shelf” or other standard products); or (iii) provisions
restricting the development, manufacture or distribution of the
Company’s or any of its Subsidiaries products or services; or
(iv) indemnification by the Company or any of its Subsidiaries
with respect to infringements of proprietary rights.
(b) Since June 30, 2007
(the “ Balance Sheet Date ”), neither the
Company nor any of its Subsidiaries has, except in the ordinary
course of business: (i) declared or paid
4
any dividends, or authorized
or made any distribution upon or with respect to any class or
series of its capital stock; (ii) incurred any indebtedness
for money borrowed or any other liabilities (other than ordinary
course obligations) individually in excess of $50,000 or, in the
case of indebtedness and/or liabilities individually less than
$50,000, in excess of $100,000 in the aggregate; (iii) made
any loans or advances to any person or entity not in excess,
individually or in the aggregate, of $100,000, other than ordinary
course advances for travel expenses; or (iv) sold, exchanged
or otherwise disposed of any of its assets or rights, other than
the sale of its inventory in the ordinary course of
business.
(c) For the purposes of
subsections (a) and (b) above, all indebtedness,
liabilities, agreements, understandings, instruments, contracts and
proposed transactions involving the same person or entity
(including persons or entities the Company or any Subsidiary of the
Company has reason to believe are affiliated therewith) shall be
aggregated for the purpose of meeting the individual minimum dollar
amounts of such subsections.
(d) The Company maintains
disclosure controls and procedures (“ Disclosure
Controls ”) designed to ensure that information required
to be disclosed by the Company in the reports that it files or
submits under the Exchange Act is recorded, processed, summarized,
and reported, within the time periods specified in the rules and
forms of the Securities and Exchange Commission (“ SEC
”).
(e) The Company makes and
keep books, records, and accounts, that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of
the Company’s assets. The Company maintains internal control
over financial reporting (“ Financial Reporting
Controls ”) designed by, or under the supervision of, the
Company’s principal executive and principal financial
officers, and effected by the Company’s board of directors,
management, and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in
accordance with generally accepted accounting principles (“
GAAP ”) as implemented by the SEC for reporting
companies, including that:
(i) transactions are executed
in accordance with management’s general or specific
authorization;
(ii) unauthorized
acquisition, use, or disposition of the Company’s assets that
could have a material effect on the financial statements are
prevented or timely detected;
(iii) transactions are
recorded as necessary to permit preparation of financial statements
in accordance with GAAP, and that the Company’s receipts and
expenditures are being made only in accordance with authorizations
of the Company’s management and board of
directors;
(iv) transactions are
recorded as necessary to maintain accountability for assets;
and
5
(v) the recorded
accountability for assets is compared with the existing assets at
reasonable intervals, and appropriate action is taken with respect
to any differences.
(f) There is no weakness in
any of the Company’s Disclosure Controls or Financial
Reporting Controls that is required to be disclosed in any of the
Exchange Act Filings, except as so disclosed.
4.7 Obligations to Related
Parties . Except as set forth on Schedule 4.7, there are no
obligations of the Company or any of its Subsidiaries to officers,
directors, stockholders or employees of the Company or any of its
Subsidiaries other than:
(a) for payment of salary for
services rendered and for bonus payments;
(b) reimbursement for
reasonable expenses incurred on behalf of the Company and its
Subsidiaries;
(c) for other standard
employee benefits made generally available to all employees
(including stock option agreements outstanding under any stock
option plan approved by the Board of Directors of the Company and
each Subsidiary of the Company, as applicable); and
(d) obligations listed in the
Company’s and each of its Subsidiary’s financial
statements or disclosed in any of the Company’s Exchange Act
Filings.
Except as described above or set forth
on Schedule 4.7, none of the officers, directors or, to the best of
the Company’s knowledge, key employees or stockholders of the
Company or any of its Subsidiaries or any members of their
immediate families, are indebted to the Company or any of its
Subsidiaries, individually or in the aggregate, in excess of
$50,000 or have any direct or indirect ownership interest in any
firm or corporation with which the Company or any of its
Subsidiaries is affiliated or with which the Company or any of its
Subsidiaries has a business relationship, or any firm or
corporation which competes with the Company or any of its
Subsidiaries, other than passive investments in publicly traded
companies (representing less than one percent (1%) of such
company) which may compete with the Company or any of its
Subsidiaries. Except as described above, no officer, director or
stockholder of the Company or any of its Subsidiaries, or any
member of their immediate families, is, directly or indirectly,
interested in any material contract with the Company or any of its
Subsidiaries and no agreements, understandings or proposed
transactions are contemplated between the Company or any of its
Subsidiaries and any such person. Except as set forth on Schedule
4.7, neither the Company nor any of its Subsidiaries is a guarantor
or indemnitor of any indebtedness of any other person or
entity.
4.8 Changes . Since
the Balance Sheet Date, except as disclosed in any Exchange Act
Filing or in any Schedule to this Agreement or to any of the
Related Agreements, there has not been:
(a) except for additional
loan disbursements by Accentia Biopharmaceuticals, Inc., a Florida
corporation (the “ Parent ”) to the Company
under those certain demand
6
notes issued by the Company
to the Parent (the “ Parent Disbursements ”),
any change in the business, assets, liabilities, condition
(financial or otherwise), properties, operations or prospects of
the Company or any of its Subsidiaries, which individually or in
the aggregate has had, or could reasonably be expected to have,
individually or in the aggregate, a Material Adverse
Effect;
(b) any resignation or
termination of any officer, key employee or group of employees of
the Company or any of its Subsidiaries;
(c) except for the Parent
Disbursements, any material change, except in the ordinary course
of business, in the contingent obligations of the Company or any of
its Subsidiaries by way of guaranty, endorsement, indemnity,
warranty or otherwise;
(d) any damage, destruction
or loss, whether or not covered by insurance, which has had, or
could reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect;
(e) any waiver by the Company
or any of its Subsidiaries of a valuable right or of a material
debt owed to it;
(f) any direct or indirect
loans made by the Company or any of its Subsidiaries to any
stockholder, employee, officer or director of the Company or any of
its Subsidiaries, other than advances made in the ordinary course
of business;
(g) any material change in
any compensation arrangement or agreement with any employee,
officer, director or stockholder of the Company or any of its
Subsidiaries;
(h) any declaration or
payment of any dividend or other distribution of the assets of the
Company or any of its Subsidiaries;
(i) any labor organization
activity related to the Company or any of its
Subsidiaries;
(j) any debt, obligation or
liability incurred, assumed or guaranteed by the Company or any of
its Subsidiaries, except for (i) the Parent Disbursements, and
(ii) those immaterial amounts and for current liabilities
incurred in the ordinary course of business;
(k) any sale, assignment or
transfer of any patents, trademarks, copyrights, trade secrets or
other intangible assets owned by the Company or any of its
Subsidiaries;
(l) any change in any
material agreement to which the Company or any of its Subsidiaries
is a party or by which either the Company or any of its
Subsidiaries is bound which either individually or in the aggregate
has had, or could reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect;
7
(m) any other event or
condition of any character that, either individually or in the
aggregate, has had, or could reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect;
or
(n) any arrangement or
commitment by the Company or any of its Subsidiaries to do any of
the acts described in subsection (a) through
(m) above.
4.9 Title to Properties
and Assets; Liens, Etc . Except as set forth on
Schedule 4.9, each of the Company and each of its Subsidiaries
has good and marketable title to its properties and assets, and
good title to its leasehold interests, in each case subject to no
mortgage, pledge, lien, lease, encumbrance or charge, other
than:
(a) those resulting from
taxes which have not yet become delinquent;
(b) minor liens and
encumbrances which do not materially detract from the value of the
property subject thereto or materially impair the operations of the
Company or any of its Subsidiaries, so long as in each such case,
such liens and encumbrances have no effect on the lien priority of
the Purchaser in such property; and
(c) those that have otherwise
arisen in the ordinary course of business, so long as they have no
effect on the lien priority of the Purchaser therein.
All facilities, machinery, equipment,
fixtures, vehicles and other properties owned, leased or used by
the Company and its Subsidiaries are in good operating condition
and repair and are reasonably fit and usable for the purposes for
which they are being used. Except as set forth on Schedule 4.9, the
Company and its Subsidiaries are in compliance with all material
terms of each lease to which it is a party or is otherwise
bound.
4.10 Intellectual
Property .
(a) Each of the Company and
each of its Subsidiaries owns or possesses sufficient legal rights
to all patents, trademarks, service marks, trade names, copyrights,
trade secrets, licenses, information and other proprietary rights
and processes necessary for its business as now conducted and, to
the Company’s knowledge, as presently proposed to be
conducted (the “ Intellectual Property ”),
without any known infringement of the rights of others. There are
no outstanding options, licenses or agreements of any kind relating
to the foregoing proprietary rights, nor is the Company or any of
its Subsidiaries bound by or a party to any options, licenses or
agreements of any kind with respect to the patents, trademarks,
service marks, trade names, copyrights, trade secrets, licenses,
information and other proprietary rights and processes of any other
person or entity other than such licenses or agreements arising
from the purchase of “off the shelf” or standard
products.
(b) Neither the Company nor
any of its Subsidiaries has received any communications alleging
that the Company or any of its Subsidiaries has violated any of the
patents, trademarks, service marks, trade names, copyrights or
trade secrets or other proprietary rights of any other person or
entity, nor is the Company or any of its Subsidiaries aware of any
basis therefor.
8
(c) The Company does not
believe it is or will be necessary to utilize any inventions, trade
secrets or proprietary information of any of its employees made
prior to their employment by the Company or any of its
Subsidiaries, except for inventions, trade secrets or proprietary
information that have been rightfully assigned to the Company or
any of its Subsidiaries.
4.11 Compliance with Other
Instruments . Neither the Company nor any of its Subsidiaries
is in violation or default of (x) any term of its Charter or
Bylaws, or (y) any provision of any indebtedness, mortgage,
indenture, contract, agreement or instrument to which it is party
or by which it is bound or of any judgment, decree, order or writ,
which violation or default, in the case of this clause (y), has
had, or could reasonably be expected to have, either individually
or in the aggregate, a Material Adverse Effect. The execution,
delivery and performance of and compliance with this Agreement and
the Related Agreements to which it is a party, and the issuance and
sale of the Note by the Company and the other Securities, if any,
by the Company each pursuant hereto and thereto, will not, with or
without the passage of time or giving of notice, result in any such
material violation, or be in conflict with or constitute a default
under any such term or provision, or result in the creation of any
mortgage, pledge, lien, encumbrance or charge upon any of the
properties or assets of the Company or any of its Subsidiaries or
the suspension, revocation, impairment, forfeiture or nonrenewal of
any permit, license, authorization or approval applicable to the
Company, its business or operations or any of its assets or
properties.
4.12 Litigation .
Except as set forth on Schedule 4.12 hereto, there is no action,
suit, proceeding or investigation pending or, to the
Company’s knowledge, currently threatened against the Company
or any of its Subsidiaries that prevents the Company or any of its
Subsidiaries from entering into this Agreement or the other Related
Agreements, or from consummating the transactions contemplated
hereby or thereby, or which has had, or could reasonably be
expected to have, either individually or in the aggregate, a
Material Adverse Effect or any change in the current equity
ownership of the Company or any of its Subsidiaries, nor is the
Company aware that there is any basis to assert any of the
foregoing. Neither the Company nor any of its Subsidiaries is a
party to or subject to the provisions of any order, writ,
injunction, judgment or decree of any court or government agency or
instrumentality. There is no action, suit, proceeding or
investigation by the Company or any of its Subsidiaries currently
pending or which the Company or any of its Subsidiaries intends to
initiate.
4.13 Tax Returns and
Payments . Each of the Company and each of its Subsidiaries has
timely filed all tax returns (federal, state and local) required to
be filed by it. All taxes shown to be due and payable on such
returns, any assessments imposed, and all other taxes due and
payable by the Company or any of its Subsidiaries on or before the
Closing, have been paid or will be paid prior to the time they
become delinquent. Except as set forth on Schedule 4.13,
neither the Company nor any of its Subsidiaries has been
advised:
(a) that any of its returns,
federal, state or other, have been or are being audited as of the
date hereof; or
(b) of any adjustment,
deficiency, assessment or court decision in respect of its federal,
state or other taxes.
9
The Company has no knowledge of any
liability for any tax to be imposed upon its properties or assets
as of the date of this Agreement that is not adequately provided
for.
4.14 Employees .
Except as set forth on Schedule 4.14, neither the Company nor any
of its Subsidiaries has any collective bargaining agreements with
any of its employees. There is no labor union organizing activity
pending or, to the Company’s knowledge, threatened with
respect to the Company or any of its Subsidiaries. Except as
disclosed in the Exchange Act Filings or on Schedule 4.14, neither
the Company nor any of its Subsidiaries is a party to or bound by
any currently effective employment contract, deferred compensation
arrangement, bonus plan, incentive plan, profit sharing plan,
retirement agreement or other employee compensation plan or
agreement. To the Company’s knowledge, no employee of the
Company or any of its Subsidiaries, nor any consultant with whom
the Company or any of its Subsidiaries has contracted, is in
violation of any term of any employment contract, proprietary
information agreement or any other agreement relating to the right
of any such individual to be employed by, or to contract with, the
Company or any of its Subsidiaries because of the nature of the
business to be conducted by the Company or any of its Subsidiaries;
and to the Company’s knowledge the continued employment by
the Company and its Subsidiaries of their present employees, and
the performance of the Company’s and its Subsidiaries’
contracts with its independent contractors, will not result in any
such violation. Neither the Company nor any of its Subsidiaries is
aware that any of its employees is obligated under any contract
(including licenses, covenants or commitments of any nature) or
other agreement, or subject to any judgment, decree or order of any
court or administrative agency that would interfere with their
duties to the Company or any of its Subsidiaries. Neither the
Company nor any of its Subsidiaries has received any notice
alleging that any such violation has occurred. Except for employees
who have a current effective employment agreement with the Company
or any of its Subsidiaries, no employee of the Company or any of
its Subsidiaries has been granted the right to continued employment
by the Company or any of its Subsidiaries or to any material
compensation following termination of employment with the Company
or any of its Subsidiaries. Except as set forth on Schedule 4.14,
the Company is not aware that any officer, key employee or group of
employees intends to terminate his, her or their employment with
the Company or any of its Subsidiaries, nor does the Company or any
of its Subsidiaries have a present intention to terminate the
employment of any officer, key employee or group of
employees.
4.15 Registration Rights
and Voting Rights . Except as set forth on Schedule 4.15
and except as disclosed in Exchange Act Filings, neither the
Company nor any of its Subsidiaries is presently under any
obligation, and neither the Company nor any of its Subsidiaries has
granted any rights, to register any of the Company’s or its
Subsidiaries’ presently outstanding securities or any of its
securities that may hereafter be issued. Except as set forth on
Schedule 4.15 and except as disclosed in Exchange Act Filings, to
the Company’s knowledge, no stockholder of the Company or any
of its S
|